LI Yulong, DONG Qiangli, ZHANG Lan. Research progress of selective serotonin reuptake inhibitor in treatment of adolescent depression[J]. Journal of Clinical Medicine in Practice, 2022, 26(11): 138-142, 148. DOI: 10.7619/jcmp.20214733
Citation: LI Yulong, DONG Qiangli, ZHANG Lan. Research progress of selective serotonin reuptake inhibitor in treatment of adolescent depression[J]. Journal of Clinical Medicine in Practice, 2022, 26(11): 138-142, 148. DOI: 10.7619/jcmp.20214733

Research progress of selective serotonin reuptake inhibitor in treatment of adolescent depression

  • In recent years, the incidence of depression in adolescents has been increasing year by year, resulting in impairment of their academic, social, family and other social functions, and even adverse events such as self-injury and suicide, which seriously damages the physical and mental health of adolescents and brings a heavy burden to families and society. Pharmacotherapy is the main treatment modality for adolescent depression, among which selective serotonin reuptake inhibitor (SSRI) is the most widely used, and it has better efficacy and tolerability in adolescent depression. However, there are widespread clinical problems such as off-label drug use, adverse reactions, and unclear correlation between SSRI and suicide risk of adolescent depression. In this article, we summarized the relevant content of SSRI in the treatment of adolescent depression, aiming to provide a reference for clinicians to develop medication regimens.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return